About [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone
[4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone (PubChem CID 156640480) has the molecular formula C30H26F2N10O2
and a molecular weight of 596.60 g/mol. Its IUPAC name is [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone.
Molecular Properties
| Compound Name | [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone |
| PubChem CID | 156640480 |
| Molecular Formula | C30H26F2N10O2 |
| Molecular Weight | 596.60 g/mol |
| Exact Mass | 596.22 |
| IUPAC Name | [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone |
| SMILES | Cc1cn(-c2ccc3oc(-c4ccnc(C(=O)N5CCN(C(c6ccccc6)c6nnn(C(F)F)n6)CC5)c4)nc3c2)cn1 |
| InChI | InChI=1S/C30H26F2N10O2/c1-19-17-41(18-34-19)22-7-8-25-23(16-22)35-28(44-25)21-9-10-33-24(15-21)29(43)40-13-11-39(12-14-40)26(20-5-3-2-4-6-20)27-36-38-42(37-27)30(31)32/h2-10,15-18,26,30H,11-14H2,1H3 |
| InChIKey | CURHIKCHWJOQAB-UHFFFAOYSA-N |
| XLogP | 4.31 |
| TPSA | 123.89 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 11 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 44 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
| MW ≤ 500 | 596.60 |
| LogP ≤ 5 | 4.31 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 11 |
Analyze [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone with MolForge
Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.
Launch Full Analysis
Frequently Asked Questions
What is the IUPAC name of [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone?
The IUPAC name of [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone (CID 156640480) is [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone.
What is the SMILES notation for [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone?
The canonical SMILES for [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone is Cc1cn(-c2ccc3oc(-c4ccnc(C(=O)N5CCN(C(c6ccccc6)c6nnn(C(F)F)n6)CC5)c4)nc3c2)cn1.
What is the InChIKey of [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone?
The InChIKey is CURHIKCHWJOQAB-UHFFFAOYSA-N. The full InChI is InChI=1S/C30H26F2N10O2/c1-19-17-41(18-34-19)22-7-8-25-23(16-22)35-28(44-25)21-9-10-33-24(15-21)29(43)40-13-11-39(12-14-40)26(20-5-3-2-4-6-20)27-36-38-42(37-27)30(31)32/h2-10,15-18,26,30H,11-14H2,1H3.
What are the key properties of [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone?
[4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone has a molecular weight of 596.60 g/mol, XLogP of 4.31, 7 rotatable bonds, 0 hydrogen bond donors, and 11 hydrogen bond acceptors.
Where does this data come from?
All data for [4-[[2-(difluoromethyl)tetrazol-5-yl]-phenylmethyl]piperazin-1-yl]-[4-[5-(4-methylimidazol-1-yl)-1,3-benzoxazol-2-yl]-2-pyridinyl]methanone is sourced from PubChem (CID 156640480), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).